Home > Business Cases > In-licensing decisions

In-licensing decisions

European BioPharma, model based in-licensing.
Problem: paying milestone payments before entering in Phase II for a NCE for pain?
Direct hERG inhibition assay was negative, but Anaxomics safety analysis showed that QTc prolongation was likely to occur.
Extensive in vivo analysis suggested cardiotoxicity.
Sponsor saved money and chose other candidates

Please, contact us here to request more information.